Senseonics Holdings, Inc. (NYSE MKT:SENS) Q4 2018 Earnings Conference Call - Final Transcript
Mar 12, 2019 • 04:30 pm ET
Good day, everyone, and welcome to today's Senseonics Fourth Quarter 2018 Earnings Conference. Today's conference is being recorded. After today's presentation, there will be an opportunity to ask questions. (Operator Instructions) At this time, I would like to turn the conference over to Philip Taylor, Please go ahead.
Thank you very much, and welcome to the Senseonics fourth quarter 2018 earnings conference call. This is Philip Taylor from the Gilmartin Group. Before we begin today, let me remind you that the Company's remarks include forward-looking statements. These statements reflect management's expectations about future events, operating plans, regulatory matters, product enhancements, Company performance and other matters and speak only as of the date hereof. These forward-looking statements involve a number of risks and uncertainties.
A list of the factors that could cause actual results to be materially different from those expressed or implied by any of these forward-looking statements is detailed under Risk Factors and elsewhere in our Annual Report on Form 10-K and our other reports filed with the SEC. These documents are available in the Investor Relations section of our website at www.senseonics.com. We undertake no obligation to update publicly or revise these forward-looking statements for any reason except as required by law.
Also on this call, we will be discussing our full year 2019 revenue guidance which was also included in the press release. In light of Regulation FD, we advice you that it is Senseonics' policy not to comment on our financial guidance other than in public communications. Joining me from Senseonics are Tim Goodnow, President and CEO; and Jon Isaacson, CFO.
With that, I would like to turn the call over to Tim Goodnow, President and CEO. Tim?
Timothy T. Goodnow
Thank you, Taylor, and thank you all for joining this afternoon. Today I'll provide a brief update on our business. First, discussing developments and initiatives in the United States and then sharing progress on the regulatory pipeline and European fronts. Jon will provide details on our financial results and outlook and then we'll open up the call to questions.
First, let me begin, as we released last week, I'm pleased to welcome Dr. Fran Kaufman to Senseonics as our new Chief Medical Officer. For those of you who don't know her, Fran is one of the leading clinical endocrinologists here at home and abroad and we're thrilled to have her on board. She's a past President of the American Diabetes Association and has published extensively in clinical and scientific journals throughout her career. Fran is an avid patient advocate and continues to treat patients with diabetes. She joined us after spending a number of years in a similar role for a large global diabetes company. We're confident that her knowledge, experience and leadership will have a positive impact on our success and we're excited that she's on board.
As we spoke about on our last call, in our first half year on the market with Eversense in the United States, we've made significant inroads with patients, payers and providers,